Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
De Francia S, D'Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di Carlo F, Di Perri G. De Francia S, et al. Among authors: saglio g. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jun 15;877(18-19):1721-6. doi: 10.1016/j.jchromb.2009.04.028. Epub 2009 Apr 24. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19428316
Emerging drugs for chronic myeloid leukemia.
Cilloni D, Messa E, Rotolo A, Saglio G. Cilloni D, et al. Among authors: saglio g. Expert Opin Emerg Drugs. 2010 Jun;15(2):175-84. doi: 10.1517/14728211003621220. Expert Opin Emerg Drugs. 2010. PMID: 20201747 Review.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Saglio G, et al. Cancer. 2010 Aug 15;116(16):3852-61. doi: 10.1002/cncr.25123. Cancer. 2010. PMID: 20564086 Free PMC article. Clinical Trial.
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Cortés JE; Panel at the Third Global Workshop on Chronic Myeloid Leukemia. Saglio G, et al. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):443-51. doi: 10.3816/CLML.2010.n.077. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21156461 Review.
634 results